Structural investigations and antibacterial, antifungal and anticancer studies on zinc salicylaldimine complexes.

IF 3.2 4区医学 Q3 CHEMISTRY, MEDICINAL Future medicinal chemistry Pub Date : 2024-08-02 Epub Date: 2024-06-20 DOI:10.1080/17568919.2024.2363672

Ahmed Bm Ibrahim, Ereny S Williem, S Abd Elkhalik, Alexander Villinger, S M Abbas

{"title":"Structural investigations and antibacterial, antifungal and anticancer studies on zinc salicylaldimine complexes.","authors":"Ahmed Bm Ibrahim, Ereny S Williem, S Abd Elkhalik, Alexander Villinger, S M Abbas","doi":"10.1080/17568919.2024.2363672","DOIUrl":null,"url":null,"abstract":"Aim: Zinc salicylaldimines may act as multidrug agents.Results: Three zinc salicylaldimines C1-C3 and respective ligands HL1-HL3 were examined for antimicrobial/anticancer drug action and C3 was structurally analyzed (tetrahedral, triclinic). Against two fungi, C1 inhibited Candida albicans with 12 mm (21 mm for amphotericin B). Among four bacteria, two ligands inhibited Staphylococcus aureus and Escherichia coli (9-10 mm), but the complexes inhibited all bacteria with 10-14 mm (21-26 mm for ampicillin). The half-maximal inhibitory concentrations for the ligands, complexes and doxorubicin were 195.5-310.7, 22.18-70.05 and 9.66 μM against cancerous MCF-7 cells and 186.4-199.9, 14.95-18.87 and 36.42 μM against normal BHK cells.Conclusion: The complexation produced pronounced enhancement in the ligand antimicrobial/anticancer activities, despite these activities are moderate comparing with standards.","PeriodicalId":12475,"journal":{"name":"Future medicinal chemistry","volume":" ","pages":"1551-1560"},"PeriodicalIF":3.2000,"publicationDate":"2024-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11370977/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future medicinal chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17568919.2024.2363672","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/20 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: Zinc salicylaldimines may act as multidrug agents.Results: Three zinc salicylaldimines C1-C3 and respective ligands HL¹-HL³ were examined for antimicrobial/anticancer drug action and C3 was structurally analyzed (tetrahedral, triclinic). Against two fungi, C1 inhibited Candida albicans with 12 mm (21 mm for amphotericin B). Among four bacteria, two ligands inhibited Staphylococcus aureus and Escherichia coli (9-10 mm), but the complexes inhibited all bacteria with 10-14 mm (21-26 mm for ampicillin). The half-maximal inhibitory concentrations for the ligands, complexes and doxorubicin were 195.5-310.7, 22.18-70.05 and 9.66 μM against cancerous MCF-7 cells and 186.4-199.9, 14.95-18.87 and 36.42 μM against normal BHK cells.Conclusion: The complexation produced pronounced enhancement in the ligand antimicrobial/anticancer activities, despite these activities are moderate comparing with standards.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

水杨醛亚胺锌复合物的结构研究及抗菌、抗真菌和抗癌研究。

目的：水杨醛亚胺锌可作为多种药物制剂。结果：研究了 C1-C3 三种水杨醛亚胺锌和各自的配体 HL1-HL3 的抗菌/抗癌作用，并对 C3 进行了结构分析（四面体、三棱体）。针对两种真菌，C1 对白色念珠菌的抑制作用为 12 毫米（对两性霉素 B 的抑制作用为 21 毫米）。在四种细菌中，两种配体对金黄色葡萄球菌和大肠杆菌的抑制作用为 9-10 毫米，但复合物对所有细菌的抑制作用为 10-14 毫米（氨苄西林为 21-26 毫米）。配体、复合物和多柔比星对癌症 MCF-7 细胞的半最大抑制浓度分别为 195.5-310.7、22.18-70.05 和 9.66 μM，对正常 BHK 细胞的半最大抑制浓度分别为 186.4-199.9、14.95-18.87 和 36.42 μM。结论尽管与标准物质相比，复配物的抗菌/抗癌活性处于中等水平，但复配物明显提高了配体的抗菌/抗癌活性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Future medicinal chemistry CHEMISTRY, MEDICINAL-

CiteScore

5.80

自引率

2.40%

发文量

118

审稿时长

4-8 weeks

期刊介绍： Future Medicinal Chemistry offers a forum for the rapid publication of original research and critical reviews of the latest milestones in the field. Strong emphasis is placed on ensuring that the journal stimulates awareness of issues that are anticipated to play an increasingly central role in influencing the future direction of pharmaceutical chemistry. Where relevant, contributions are also actively encouraged on areas as diverse as biotechnology, enzymology, green chemistry, genomics, immunology, materials science, neglected diseases and orphan drugs, pharmacogenomics, proteomics and toxicology.